When President Donald Trump was hospitalized with coronavirus disease 2019 (COVID-19), he received an experimental treatment that is still in clinical trials, including at UNC Medical Center in Chapel Hill.
Monoclonal antibody treatment uses antibodies manufactured in a laboratory that are designed to attached to the coronavirus to prevent it from entering into cells.
“This looks like a promising treatment approach,” says David A. Wohl, MD, one of the leads of COVID-19 treatment studies at UNC Medical Centerin a new UNC Health Talk article. “But we need to complete our trials before we know how effective and safe monoclonal antibodies for COVID-19 might be, particularly for people who are sick but not yet hospitalized.”
Read the article here.